Endo swallows Paladin for $1.6B

Share this article:

US-headquartered Endo Health Solutions scooped up Montreal-based specialty pharmaceutical company Paladin for $1.6 billion. The companies said in a joint statement Tuesday that while the “New Endo” will embrace both companies on the outside, the companies will have their own turf, with Paladin's current managing team continuing to lead Paladin operations from its Montreal headquarters.

Earnings accompanying the acquisition news showed a 5% decline in sales compared to the same period last year, a decrease which CEO Rajiv De Silva said was not unexpected. The company said in June it was going to overhaul its businesses through a combination of acquisitions, R&D efficiencies and trimming its operating expenses by around $325 million. The shakeup also included the departure of CFO Alan Levin, which was announced in May, and naming De Silva CEO in February.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.